News & Updates

Show Multimedia Only
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

07 Jul 2023

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

07 Jul 2023
CV health tool effectively promotes discussions during routine follow-up in cancer survivors

CV health tool effectively promotes discussions during routine follow-up in cancer survivors

06 Jul 2023 byAudrey Abella

A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.

06 Jul 2023